Trial abstracts in the registry — page 14
700 documents of type trial abstract.
Documents
-
Randomised, double-blind, placebo-controlled, phase 3 study of Teduglutide in mucosal barrier over as stated in the parent protocol. The Institute holds no reported…
Very low10 Sep 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Tesamorelin in lipodystrophy randomising 404 participants over 26 weeks. Primary result: Directionally…
Moderate08 Sep 2023 -
Randomised, double-blind, placebo-controlled, phase 2b study of Danuglipron in type 2 diabetes randomising 411 participants over 16 weeks. Primary result: Glycaemic…
07 Sep 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Dulaglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low07 Sep 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Liraglutide in type 1 diabetes (adjunct) over as stated in the parent protocol. The Institute holds no…
Very low07 Sep 2023 -
Phase 1 ascending dose, phase 1 study of PT-141 (bremelanotide) in sexual dysfunction over as stated in the parent protocol. The Institute holds no reported primary…
Very low06 Sep 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of SS-31 (elamipretide) in hfpef over as stated in the parent protocol. The Institute holds no reported…
Very low05 Sep 2023 -
Phase 1 ascending dose, phase 1 study of Exenatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low05 Sep 2023 -
Randomised crossover, phase 1 study of Tesamorelin in lipodystrophy over as stated in the parent protocol. The Institute holds no reported primary result for this record…
Very low05 Sep 2023 -
Phase 1 ascending dose, phase 1 study of Hexarelin in gh axis over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low05 Sep 2023 -
Observational, phase 3 study of Semaglutide, oral in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary…
Very low04 Sep 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of Ipamorelin in gastric emptying over in-hospital. Primary result: The programme did not proceed. The…
02 Sep 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of AOD-9604 in obesity over as stated in the parent protocol. The Institute holds no reported primary result…
Very low02 Sep 2023 -
Randomised crossover, phase 1 study of Liraglutide in sleep apnoea and obesity over as stated in the parent protocol. The Institute holds no reported primary result for…
Very low02 Sep 2023 -
Phase 1 ascending dose, phase 1 study of Tesamorelin in lipodystrophy over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low29 Aug 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide in obesity randomising 1,961 participants over 68 weeks. Primary result: Mean change −14.9 %…
High27 Aug 2023 -
Event-driven cardiovascular outcome trial, phase 3 study of Semaglutide in cardiovascular and type 2 diabetes randomising 3,297 participants over 104 weeks. Primary…
High27 Aug 2023 -
Single-arm open-label, phase 3 study of Semaglutide in obesity over open-label extension of the parent trial. The Institute holds no reported primary result for this…
Very low26 Aug 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Liraglutide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low26 Aug 2023 -
Event-driven cardiovascular outcome trial, phase 3 study of Lixisenatide in cardiovascular and type 2 diabetes randomising 6,068 participants over median 25 months…
High21 Aug 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide in type 2 diabetes randomising 388 participants over 30 weeks. Primary result: Reduction of…
High20 Aug 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Dulaglutide in type 2 diabetes and chronic kidney disease over as stated in the parent protocol. The…
Very low20 Aug 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of Thymosin beta-4 in wound healing over as stated in the parent protocol. The Institute holds no reported…
Very low18 Aug 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide in obesity randomising 611 participants over 68 weeks. Primary result: Mean change −16.0 %…
High17 Aug 2023 -
Single-arm open-label, phase 2 study of Pramlintide in obesity over open-label extension of the parent trial. The Institute holds no reported primary result for this…
Very low17 Aug 2023 -
Phase 1 ascending dose, phase 1 study of Exenatide in cardiovascular over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low17 Aug 2023 -
Event-driven cardiovascular outcome trial, phase 3 study of Exenatide in cardiovascular and type 2 diabetes randomising 14,752 participants over median 3.2 years…
High16 Aug 2023 -
Single-arm open-label, phase 3 study of SS-31 (elamipretide) in mitochondrial disease over open-label extension of the parent trial. The Institute holds no reported…
Very low16 Aug 2023 -
Randomised, double-blind, active-controlled, phase 3 study of Dulaglutide in type 2 diabetes randomising 976 participants over 26 weeks. Primary result: Superior to…
High15 Aug 2023 -
Randomised crossover, phase 1 study of PT-141 (bremelanotide) in sexual dysfunction over as stated in the parent protocol. The Institute holds no reported primary result…
Very low15 Aug 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of SS-31 (elamipretide) in mitochondrial disease over as stated in the parent protocol. The Institute holds…
Very low15 Aug 2023 -
Observational, phase 3 study of Semaglutide in cardiovascular and obesity over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low14 Aug 2023 -
Phase 1 ascending dose, phase 1 study of CJC-1295 in gh axis over multiple weekly doses. Primary result: Cumulative elevation of insulin-like growth factor 1 with…
Low13 Aug 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Liraglutide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low13 Aug 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide, oral in obesity over as stated in the parent protocol. The Institute holds no reported…
Very low13 Aug 2023 -
Randomised, double-blind, active-controlled, phase 2 study of CagriSema (cagrilintide with semaglutide) in type 2 diabetes and obesity randomising 92 participants over…
Low12 Aug 2023 -
Phase 1 ascending dose, phase 1 study of Lixisenatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low12 Aug 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Dulaglutide in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute…
Very low11 Aug 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Danuglipron in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low10 Aug 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of Retatrutide in type 2 diabetes randomising 281 participants over 36 weeks. Primary result: Reduction of up…
Moderate09 Aug 2023
page 14 of 18